Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cancer drug developer Antisoma said results from its Phase II trial evaluating its experimental lung cancer drug demonstrated positive survival rates.
Subscribe to our email newsletter
The single-arm Phase II trial evaluated a 1800mg/m2 dose of ASA404 in combination with carboplatin and paclitaxel chemotherapy in patients with non-small cell lung cancer. Median survival was 14.9 months, median time to tumor progression was 5.5 months and the tumor response rate was 37.9%. The addition of ASA404 to chemotherapy was well tolerated, Antisoma said.
These data support the findings from an earlier, randomized Phase II trial in which the addition of ASA404 to chemotherapy produced one of the largest increases in median survival ever reported in advanced lung cancer, according to the company. In that trial, patients who received a 1200mg/m2 dose of ASA404 combined with chemotherapy had a median survival of 14 months whereas patients who received chemotherapy alone had a median survival of 8.8 months.
Antisoma's partner, Novartis, plans to start enrollment of patients into a phase III trial in non-small cell lung cancer in early 2008.